Clinical Study of Adjuvant Surufatinib Therapy for Postoperative High-risk Neuroendocrine Tumors Based on the Ninth Edition of the AJCC Staging System

NCT07279532 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Neuroendocrine Neoplasms (Tumours)

Interventions

DRUG: surufatinib

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University